Assembly Biosciences Inc (ASMB) Q1 2017 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q1 2017 10-Q quarterly report on May 8, 2017 for the quarter ended Mar 31, 2017.

AI summary of MD&A and risk factor updates

Collaboration revenue $0.7M vs $0 in Q1 2016, reflecting Allergan agreement amortization
Net loss $13.9M vs $11.0M YoY, with no margin figures disclosed
Microbiome R&D expense increased $1.0M, HBV-cure R&D increased $1.2M
Operating cash flow $35.0M vs negative $9.2M YoY, driven by $49.3M deferred revenue
Allergan upfront payment $50M; cash expected to fund operations at least twelve months

No newly added or changed risks identified: section presents the comprehensive 10-K risk disclosure
Clinical development risk: ABI-H0731 Phase 1b anticipated in Q2 2017, while ABI-M101 Phase 1b planned for 2H 2017
Regulatory risk: FDA approval requires extensive nonclinical and clinical evidence, with potential additional studies or approval limits
Operational risk: third-party manufacturers supply ABI-H0731 and ABI-M101 materials without company-owned manufacturing facilities
Financial risk: accumulated deficit approximately $222.2 million, with resources expected to fund operations at least 12 months

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.